Kiadis Pharma NV (Kiadis Pharma NV) Total Liabilities : $116.40 Mil (As of Dec. 2020)

View and export this data going back to 2016. Start your Free Trial

What is Kiadis Pharma NV Total Liabilities?

Kiadis Pharma NV's Total Liabilities for the quarter that ended in Dec. 2020 was $116.40 Mil.

Kiadis Pharma NV's quarterly Total Liabilities declined from Dec. 2019 ($50.27 Mil) to Jun. 2020 ($45.64 Mil) but then increased from Jun. 2020 ($45.64 Mil) to Dec. 2020 ($116.40 Mil).

Kiadis Pharma NV's annual Total Liabilities increased from Dec. 2018 ($43.69 Mil) to Dec. 2019 ($50.27 Mil) and increased from Dec. 2019 ($50.27 Mil) to Dec. 2020 ($116.40 Mil).

Kiadis Pharma NV Total Liabilities Historical Data

The historical data trend for Kiadis Pharma NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Total Liabilities Chart

Kiadis Pharma NV Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Liabilities

Get a 7-Day Free Trial

20.86

34.12

43.69

50.27

116.40

Kiadis Pharma NV Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
Total Liabilities	Get a 7-Day Free Trial											43.69	72.08	50.27	45.64	116.40

Kiadis Pharma NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kiadis Pharma NV's Total Liabilities for the fiscal year that ended in Dec. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	103.022	+	(6.527	+	6.851
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	116.40

Total Liabilities	=	Total Assets (A: Dec. 2020 )	-	Total Equity (A: Dec. 2020 )
	=	76.353	-	-40.047
	=	116.40

Kiadis Pharma NV's Total Liabilities for the quarter that ended in Dec. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	103.022	+	(6.527	+	6.851
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	116.40

Total Liabilities	=	Total Assets (Q: Dec. 2020 )	-	Total Equity (Q: Dec. 2020 )
	=	76.353	-	-40.047
	=	116.40

Kiadis Pharma NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiadis Pharma NV (Kiadis Pharma NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (GREY:KIADF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP

Website

https://www.kiadis.com

Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (Kiadis Pharma NV) Headlines

No Headlines